Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Maintains Buy on CytomX Therapeutics, Lowers Price Target to $8

BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.
byBenzinga Newsdesk
July 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts